ArticleFrontiers in medicine2026
Development and validation of a nomogram to predict symptomatic recurrence following laparoscopic adenomyomectomy.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Development and external validation of a risk prediction model for hypertension among individuals with established hypothyroidism.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Nomograms are intuitive graphical tools that integrate multiple prognostic variables to generate individualized risk estimates. To date, no study has developed a validated prediction model specifically for symptomatic recurrence after uterine-sparing surgery for adenomyosis. Accordingly, this study aimed to construct and validate a nomogram based on retrospective clinical data to predict symptomatic recurrence after laparoscopic adenomyomectomy and to inform individualized postoperative management. Materials and Methods: In this retrospective cohort study, 484 consecutive patients who underwent primary laparoscopic adenomyomectomy between December 1, 2017, and March 30, 2022, were included. All patients completed postoperative follow-up. Symptomatic recurrence occurred in 131 patients, while 353 remained recurrence-free. Independent predictors of recurrence were identified using multivariate Cox regression, and a nomogram was constructed. Model discrimination was evaluated using Harrell's concordance index (C-index) and internally validated using 5-fold cross-validation. Model performance was assessed via receiver operating characteristic curve, calibration curves, and decision curve analysis. A sensitivity analysis using inverse probability of treatment weighting (IPTW) confirmed the robustness of the identified predictors against residual confounding. Results: Previous surgical history of ovarian endometrioma, preoperative CA125 level, concomitant ovarian endometrioma, postoperative medication modality, and duration of postoperative therapy were independent predictors of symptomatic recurrence. The nomogram demonstrated good discriminatory ability (area under the receiver operating characteristic curve [AUC], 0.776; 95% confidence interval [CI], 0.728-0.824). The calibration curve also had a good performance, and the DCA indicated that patients achieved a high net benefit for the predicted probability thresholds between 0% and 60%. Conclusion: This nomogram provides accurate individualized risk estimation for symptomatic recurrence after laparoscopic adenomyomectomy, which requires multicenter external validation to confirm its clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.